目的 探究注射用丹参多酚酸联合瑞舒伐他汀用于急性缺血性脑卒中治疗的效果及对脂蛋白相关磷脂酶A₂（Lp-PLA₂）、氧化修饰型低密度脂蛋白（ox-LDL）、白细胞介素-6（IL-6）表达的影响。方法 选择2020年1月—2022年10月安阳市人民医院收治的急性缺血性脑卒中患者200例为研究对象进行回顾性分析，根据治疗方案不同将患者分为对照组和试验组，每组各100例。对照组患者接受溶栓、常规对症治疗＋瑞舒伐他汀（晚饭后口服，每次10 mg，每天1次）；试验组患者在对照组基础上加用注射用丹参多酚酸，每次0.13 g，每天1次，用0.9%氯化钠注射液250 mL稀释，静脉滴注。两组均连续治疗14 d。比较两组临床疗效，比较治疗前后两组患者血清Lp-PLA₂、ox-LDL、IL-6水平及大脑中动脉（MCA）、大脑前动脉（ACA）、大脑后动脉（PCA）脑血流速度。观察治疗期间两组不良反应发生情况。结果 试验组治疗总有效率为97.00%，较对照组89.00%显著升高（P＜0.05）。治疗前，两组患者血清Lp-PLA₂、ox-LDL、IL-6水平及MCA、ACA、PCA脑血流速度比较，均无显著差异（P＞0.05）。治疗后，两组血清Lp-PLA₂、ox-LDL、IL-6均较本组治疗前显著降低（P＜0.05），且试验组低于对照组（P＜0.05）；治疗后，两组MCA、ACA、PCA脑血流速度均较本组治疗前显著升高（P＜0.05），且试验组高于对照组（P＜0.05）；两组不良反应发生率比较差异不显著（P＞0.05）。结论 注射用丹参多酚酸联合瑞舒伐他汀用于治疗急性缺血性脑卒中，不仅可改善患者脑血流速度，调节Lp-PLA₂、ox-LDL、IL-6表达，还能提高整体疗效，且安全性较高。

Objective To explore the effect of Salvianolic Acid for Injection combined with rosuvastatin in the treatment of acute ischemic stroke and its effect on the expression of lipoprotein related phospholipase A₂ (Lp-PLA₂), oxidized low-density lipoprotein (ox-LDL), and interleukin 6 (IL-6). Methods A total of 200 patients with acute ischemic stroke admitted to Anyang People's Hospital from January 2020 to October 2022 were selected for retrospective analysis. According to different treatment schemes, the patients were divided into control group and experimental group, with 100 cases in each group. The patients in the control group received thrombolysis, conventional symptomatic treatment+rosuvastatin (10 mg each time, once a day after dinner). The patients in the experimental group were added with Salvianolic Acid for Injection on the basis of the control group, 0.13 g each time, once a day, diluted with 250 mL of 0.9% Sodium Chloride Injection, and intravenous drip. Both groups were treated continuously for 14 days. The clinical efficacy of two groups was compared, and the serum levels of Lp-PLA₂, ox-LDL, IL-6, as well as the cerebral blood flow velocity of the middle cerebral artery (MCA), anterior cerebral artery (ACA), and posterior cerebral artery (PCA) were compared before and after treatment. The occurrence of adverse reactions in both groups were observed during the treatment period. Results The total effective rate of the experimental group was 97.00%, which was significantly higher than the control group's 89.00% (P＜0.05). Before treatment, there was no significant difference in the levels of serum Lp-PLA₂, ox-LDL, IL-6, cerebral blood flow velocity of MCA, ACA, and PCA between the two groups of patients (P＞0.05). After treatment, the serum levels of Lp-PLA₂, ox-LDL, and IL-6 in both groups were significantly reduced compared to before treatment in same group (P＜0.05), and the experimental group was lower than the control group (P＜0.05). After treatment, the cerebral blood flow velocity of MCA, ACA, and PCA in both groups significantly increased compared to before treatment in same group (P＜0.05), and the experimental group was higher than the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion The combination of Salvianolic Acid for Injection and rosuvastatin in the treatment of acute ischemic stroke can not only improve the cerebral blood flow velocity, regulate the expression of Lp-PLA₂, ox-LDL and IL-6, but also improve the overall efficacy and safety.

R971